BRPI0912219A2 - método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente. - Google Patents

método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente.

Info

Publication number
BRPI0912219A2
BRPI0912219A2 BRPI0912219A BRPI0912219A BRPI0912219A2 BR PI0912219 A2 BRPI0912219 A2 BR PI0912219A2 BR PI0912219 A BRPI0912219 A BR PI0912219A BR PI0912219 A BRPI0912219 A BR PI0912219A BR PI0912219 A2 BRPI0912219 A2 BR PI0912219A2
Authority
BR
Brazil
Prior art keywords
unit dose
dose form
opioid antagonist
orally administrable
peripherally acting
Prior art date
Application number
BRPI0912219A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan R Kugler
Kevin J Brodbeck
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of BRPI0912219A2 publication Critical patent/BRPI0912219A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0912219A 2008-05-07 2009-05-07 método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente. BRPI0912219A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07
PCT/US2009/002856 WO2009137086A1 (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Publications (1)

Publication Number Publication Date
BRPI0912219A2 true BRPI0912219A2 (pt) 2015-10-06

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912219A BRPI0912219A2 (pt) 2008-05-07 2009-05-07 método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente.

Country Status (15)

Country Link
US (1) US20110160239A1 (enExample)
EP (1) EP2300009A1 (enExample)
JP (1) JP2011519930A (enExample)
KR (1) KR20110004425A (enExample)
CN (1) CN102014907A (enExample)
AU (1) AU2009244805B2 (enExample)
BR (1) BRPI0912219A2 (enExample)
CA (1) CA2723685C (enExample)
EA (1) EA201001643A1 (enExample)
IL (1) IL208794A0 (enExample)
MX (1) MX2010011727A (enExample)
MY (1) MY156913A (enExample)
NZ (1) NZ589733A (enExample)
WO (1) WO2009137086A1 (enExample)
ZA (1) ZA201007531B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
MA34146B1 (fr) 2010-03-11 2013-04-03 Wyeth Llc Formulations oralles et sels lipophiles de methylnaltrexone
HRP20151420T4 (hr) * 2010-09-30 2019-04-05 Astrazeneca Ab Kristalni konjugat naloksol-peg
CN110384701A (zh) * 2011-12-19 2019-10-29 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
PT3137081T (pt) 2014-04-28 2018-02-08 Orphomed Inc Dímero de buprenorfina e o seu uso no tratamento de transtornos gastrointestinais
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6734188B1 (en) * 1999-11-01 2004-05-11 John Rhodes Composition for treatment of constipation and irritable bowel syndrome
SI1436012T1 (en) * 2001-10-18 2018-03-30 Nektar Therapeutics Polymer conjugates of opioid antagonists
PL1694363T3 (pl) * 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN101466381B (zh) * 2006-04-21 2012-11-14 尼克塔治疗公司 吗啡酮的立体选择性还原
CA2667259A1 (en) * 2006-11-07 2008-05-15 Nektar Therapeutics Al, Corporation Dosage forms and co-administration of an opioid agonist and an opioid antagonist

Also Published As

Publication number Publication date
EA201001643A1 (ru) 2011-06-30
CA2723685A1 (en) 2009-11-12
CN102014907A (zh) 2011-04-13
CA2723685C (en) 2016-09-27
AU2009244805A1 (en) 2009-11-12
IL208794A0 (en) 2010-12-30
US20110160239A1 (en) 2011-06-30
JP2011519930A (ja) 2011-07-14
ZA201007531B (en) 2012-03-28
MY156913A (en) 2016-04-15
MX2010011727A (es) 2010-11-30
EP2300009A1 (en) 2011-03-30
WO2009137086A1 (en) 2009-11-12
KR20110004425A (ko) 2011-01-13
AU2009244805B2 (en) 2013-01-10
NZ589733A (en) 2012-07-27

Similar Documents

Publication Publication Date Title
BRPI0912219A2 (pt) método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente.
FIC20253002I1 (fi) Otsanimodi, tai sen farmaseuttisesti hyväksyttävä suola, mukaan lukien hydrokloridisuola
NO2022018I1 (no) Avacopan samt farmaceutisk acceptable salte deraf
NO2020034I1 (no) Ozanimod eller et farmasøytisk akseptabelt salt derav, særlig ozanimodhydroklorid
CL2008000914A1 (es) Forma de dosificacion de liberacion modificada de tacrolimus.
DK1986650T3 (da) Manipulationssikre doserignsformer
BRPI1011414A8 (pt) "método."
FR2936709B1 (fr) Comprimes alcoolo-resistants.
EP2283446A4 (en) DETECTION OF FRAUDULOUS PAGES
IT1397291B1 (it) Dispositivo di rilevazione.
BRPI0918760A2 (pt) compostos morfinanos
BRPI0814466A2 (pt) Método.
EP2069930A4 (en) ADVANCED CONTENT DETECTION
BRPI0907382A2 (pt) Antagonista de receptor de opioide seletivo capa.
SMT201400113B (it) Nalmefene cloridrato diidrato
BRPI0925077A2 (pt) Conjunto dispensador.
BRPI1016190A2 (pt) compostos farmacêuticos.
IL234296B (en) Dosing regimen
BRPI1010021A2 (pt) mandril, e, combinação do mandril
DK2081689T3 (da) Valsemølle
EP2197448A4 (en) dosing schedule
DK2252403T3 (da) Valsemølle
BRPI0807882A2 (pt) Forma de dosagem
DK2032260T3 (da) Rullemølle
BR112012004367A2 (pt) método de detecção de adulteração.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]